Bellevue Obesity Solutions B USD

Reference Data

ISIN LU0415392322
Valor Number 3882743
Bloomberg Global ID BBG000JKZJQ6
Fund Name Bellevue Obesity Solutions B USD
Fund Provider Bellevue Asset Management AG Zürich, Switzerland
Phone: +41 44 267 67 00
E-Mail: info@bellevue.ch
Web: www.bellevue.ch
Fund Provider Bellevue Asset Management AG
Representative in Switzerland Waystone Fund Services (Switzerland) SA
Lausanne
Phone: 0041213111781
Distributor(s) Bank am Bellevue AG
Küsnacht
Phone: +41 44 267 67 67
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The investment objective of the fund is to achieve long-term capital growth by investing at least two thirds of the net assets in a portfolio of carefully chosen shares and preference shares of companies whose business is directed towards the prevention and treatment of overweight or obesity and their secondary conditions or companies whose main activity involves holding investments in such companies or financing such companies and that have their registered office or carry out the majority of their economic activity in recognised countries.
Peculiarities

Fund Prices

Current Price * 486.52 USD 02.04.2025
Previous Price * 485.03 USD 01.04.2025
52 Week High * 565.57 USD 30.08.2024
52 Week Low * 479.21 USD 20.12.2024
NAV * 486.52 USD 02.04.2025
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 35,205,372
Unit/Share Assets ***
Trading Information SIX

Performance

YTD Performance +1.30% 31.12.2024
02.04.2025
YTD Performance (in CHF) -1.59% 31.12.2024
02.04.2025
1 month -5.31% 03.03.2025
02.04.2025
3 months +1.09% 02.01.2025
02.04.2025
6 months -9.78% 02.10.2024
02.04.2025
1 year -4.52% 02.04.2024
02.04.2025
2 years -6.66% 03.04.2023
02.04.2025
3 years -13.97% 04.04.2022
02.04.2025
5 years +15.85% 02.04.2020
02.04.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Eli Lilly and Co 9.94%
UnitedHealth Group Inc 6.94%
Johnson & Johnson 5.92%
AbbVie Inc 5.68%
Novo Nordisk AS Class B 4.34%
Intuitive Surgical Inc 3.84%
AstraZeneca PLC ADR 3.59%
Roche Holding AG 3.53%
Abbott Laboratories 3.51%
Thermo Fisher Scientific Inc 3.47%
Last data update 28.02.2025

Cost / Risk

TER 2.26%
TER date 01.02.2021
Performance Fee *** 0.00%
PTR
Max. Management Fee *** 1.60%
Ongoing Charges *** 2.17%
SRRI ***
SRRI date *** 31.03.2025

Breakdowns

Countries ***

Stock Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)